Single-And repeated-dose oral toxicity studies of Citicoline free-base (choline cytidine 5'-pyrophosphate) in Sprague-Dawley rats

International Journal of Toxicology

Volumn 28, Issue 6, 2009, Pages 479-487

  Schauss, A G ^a   Somfai Relle, S ^b   Financsek, I ^b   Glavits, R ^c   Parent, S C ^a   Endres, J R ^a   Varga, T ^b   Szucs Z ^b   Clewell, A ^a  

^a Natural and Medicinal Products Research   (United States)

^b Pharmaceutical Control and Development Laboratory Ltd   (Hungary)

^c CENTRAL VETERINARY INSTITUTE   (Hungary)

Author keywords

13 week subchronic toxicity study; Acute toxicity study (limit test); Cdp choline; Choline cytidine 5' pyrophosphate; Citicoline; Citicoline free base; Dietary supplement; Nootropic agent; Sprague Dawley rats

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CALCIUM; CHOLESTEROL; CITICOLINE; CREATININE; HEMOGLOBIN; PHOSPHORUS;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHRONIC TOXICITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIET SUPPLEMENTATION; DIETARY INTAKE; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG TOLERABILITY; DRUG TOLERANCE; FEEDING; FEMALE; FLUID INTAKE; HISTOPATHOLOGY; INFLAMMATION; KIDNEY MASS; KIDNEY TUBULE; MALE; MINERALIZATION; MORTALITY; NONHUMAN; RAT; RELATIVE DENSITY; SPRAGUE DAWLEY RAT; TOXICITY TESTING; UREA NITROGEN BLOOD LEVEL; URINE PH; URINE VOLUME;

ADMINISTRATION, ORAL; ANIMALS; BLOOD CELL COUNT; BLOOD CHEMICAL ANALYSIS; CALCINOSIS; CREATININE; CYTIDINE DIPHOSPHATE CHOLINE; FEMALE; KIDNEY; KIDNEY DISEASES; KIDNEY TUBULES; LETHAL DOSE 50; MALE; NOOTROPIC AGENTS; ORGAN SIZE; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; URODYNAMICS;

RATTUS;

EID: 73549096195     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1177/1091581809349452     Document Type: Article

References (37)

1. Adibhatla RM, Hatcher JF. Citicoline mechanisms and clinical efficacy in cerebral ischemia. J Neurosci Res. 2002;70:133-139.
2. O'Neil MJ. The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals. 14th ed. Whitehouse Station, NJ: Merck; 2006.
3. Secades JJ, Frontera G. CDP-choline: pharmacological and clinical review. Methods Find Exp Clin Pharmacol. 1995;17(suppl B):1-54.
4. Conant R, Schauss AG. Therapeutic applications of citicoline for stroke and cognitive dysfunction in the elderly: a review of the literature. Altern Med Rev. 2004;9:17-31.
5. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev. 2005;(2):CD000269.
6. Citicoline monograph. Altern Med Rev. 2008;13:50-57.
7. Clark WM, Warach SJ, Pettigrew LC, et al. A randomized doseresponse trial of citicoline in acute ischemic stroke patients. Neurology. 1997;49:671-678.
8. Clark WM, Wechsler LR, Sabounjian LA, et al. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology. 2001;57:1595-1602.
9. Davalos A, Castillo J, Alvarez-Sabin J, et al. Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke. 2002;33:2850-2857.
10. Parisi V, Manni G, Colacino G, et al. Cytidine-5'-diphosphocholine (citicoline) improves retinal and cortical responses in patients with glaucoma. Ophthalmology. 1999;106:1126-1134.
11. Grieb P, Rejdak R. Pharmacodynamics of citicoline relevant to the treatment of glaucoma. J Neurosci Res. 2002;67:143-148.
12. Silveri MM, Dikan J, Ross AJ, et al. Oral citicoline supplementation significantly alters phosphorus metabolites in the anterior cingulate cortex. Poster presented at: Society for Neuroscience; November 4th, 2007; San Diego, Calif.
13. Romero A, Grau T, Sacristan A, et al. Study of subacute toxicity of CDP-choline after 30 days of oral administration to rats. Arzneim.-Forsch. 1983;33:1035-1038.
14. Romero A, Grau T, Sacristan A, et al. CDP-choline: 6-month study on toxicity in dogs. Arzneim.-Forsch. 1983;33:1038-1042.
15. Grau T, Romero A, Sacristan A, et al. CDP-choline: acute toxicity study. Arzneim.-Forsch. 1983;33:1033-1034.
16. Woodard JC. A morphologic and biochemical study of nutritional nephrocalcinosis in female rats fed semipurified diets. Am J Pathol. 1971;65:253-268.
17. Montgomery CA, Seely JC. Kidney. In: Pathology of the Fischer Rat, Reference and Atlas. Boorman GA, Eustis SL, Elwell MR, et al, eds. New York, NY: Academic Press; 1990.
18. Dixon D, Heider K, Elwell MR. Incidence of nonneoplastic lesions in historical control male and female Fischer-344 rats from 90-day toxicity studies. Toxicol Pathol. 1995;23:338-348.
19. Ritskes-Hoitinga J, Lemmens AG, Beynen AC. Nutrition and kidney calcification in rats. Lab Anim. 1989;23:313-318.
20. Vandenberghe J. Life-Span Data and Historical Data in Carcinogenicity Testing in Wistar Rats Crl: (Wi) BR. Beerse, Belgium: Janssen Research Foundation, Department of Toxicology, Janssen Pharmacentica NV; 1990.
21. Meyer O, Blom L, Olsen P. Influence of diet and strain of rat on kidney damage observed in toxicity studies. Arch Toxicol Suppl. 1978;1:355-358.
22. Owen RA, Heywood R. Age related variations in renal structure and function in Sprague-Dawley rats. Toxicol Pathol. 1986;14:158-67.
23. Al-Modhefer AKJ, Atherton JC, Garland HO, et al. Kidney function in rats with corticomedullary nephrocalcinosis: effects of alteration in dietary calcium and magnesium. J Physiol. 1986;380:405-414.
24. Rao GN. New nonpurified diet (NTP-2000) for rodents in the National Toxicology Program's toxicology and carcinogenesis studies. J Nutr. 1997;127:842S-846S.
25. Cockell KA, L'Abbe MR, Belonje B. The concentrations and ratio of dietary calcium and phosphorus influence development of nephrocalcinosis in female rats. J Nutr. 2002;132: 252-256.
26. Matsuzaki H, Katsumata S, Masuyama R, et al. Sex differences in kidney mineral concentrations and urinary albumin excretion in rats given high-phosphorus feed. Biosci Biotechnol Bio Chem. 2002;66:1737-1739.
27. Cousins FB, Geary CPM. A sex-determined renal calcification in rats. Nature. 1966;211:980-981.
28. Kaunitz H, Johnson RE. Dietary protein, fat, and nephrocalcinosis in female rats. Metabolism. 1976;25:69-77.
29. Schaafsma G, Duursma SA, Visser WJ, et al. The influence of dietary calcium on kidney calcification and renal function in rats fed high-phosphate diets. Bone. 1985; 6:155-163.
30. Ritskes-Hoitinga J, Lemmens AG, Danse LHJC, et al. Phosphorus-induced nephrocalcinosis and kidney function in female rats. J Nutr. 1989;1423:1989.
31. Matsuzaki H, Kikuchi T, Kajita, et al. Comparison of various phosphate salts as the dietary phosphorous source on nephrocalcinosis and kidney function. J Nutr Sci Vitaminol (Tokyo). 1999;45:595-608.
32. Grimm P, Nowitzki S, Classen HG. Nephrocalcinosis without functional renal impairment in rats subjected to subacute moderate magnesium deficiency, and intervention studies on mobilization of calcium deposits. Magnesium Res. 1990;3:87-92.
33. Gad S. Animal Models in Toxicology. 2nd ed. Boca Raton, FL: CRC Press; 2007.
34. FSIS meal labeling rules 9 CFR 317.309. In: FDA and USDA Nutrition Labeling Guide Decisions, Diagrams, Checklists, and Regulations. Altman TA, ed. Boca Raton, FL: CRC Press; 1988:10, 32.
35. Food and Nutritional Board, Institute of Medicine. Phosphorus. In: Background Information in Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Washington, DC: National Academy Press; 1999.
36. G.-Coviella I, Agut J, Von Borstel R, et al. Metabolism of citidine (5') diphosphocholine (CDP-coline) following oral and intravenous administration to the human and the rat. Neurochem Int. 1987;11:293-297.
37. Wurtman RJ, Regan M, Ulus I, et al. Effect of oral CDP choline on plasma choline and uridine levels in humans. Biochem Pharmacol. 2000;60:989-992.